Table 2.

Characteristics of patients according to IV bDMARD. Values are % unless otherwise specified.

Characteristics	Abatacept	Infliximab	Tocilizumab	p^*
Patients, n (%)	129 (22.9)	213 (37.9)	221 (39.2)
Total time taking drug, mos, mean (SD)	27.4 (21.3)	41.7 (33.3)	31.1 (22.3)	0.03
Diagnosis
Rheumatoid arthritis	98.4	31.9	92.3
Axial spondyloarthritis	—	51.7	—
Psoriatic arthritis	—	13.6	—
JIA	1.6	2.8	7.2
Concomitant sDMARD^**
Methotrexate	59.6	44.6	66.8	< 0.001
Leflunomide	12.4	2.34	5.4	< 0.001
Corticosteroids	48.9	49.9	50.6	0.46

↵* p values are supplemented as appropriate.
↵** At baseline. IV: intravenous; DMARD: disease-modifying antirheumatic drugs; bDMARD: biological DMARD; JIA: juvenile idiopathic arthritis; sDMARD: synthetic DMARD.